Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the fifteen brokerages that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $31.33.
MLTX has been the topic of a number of recent research reports. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of MoonLake Immunotherapeutics in a report on Monday, October 5th. Cantor Fitzgerald reissued an "overweight" rating on shares of MoonLake Immunotherapeutics in a research report on Wednesday, September 16th. Wall Street Zen lowered shares of MoonLake Immunotherapeutics from a "sell" rating to a "strong sell" rating in a research note on Sunday, September 27th. Weiss Ratings downgraded shares of MoonLake Immunotherapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday. Finally, Chardan Capital assumed coverage on shares of MoonLake Immunotherapeutics in a report on Friday, November 6th. They set a "buy" rating and a $57.00 price objective on the stock.
Get Our Latest Analysis on MLTX
Institutional Investors Weigh In On MoonLake Immunotherapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the business. Allworth Financial LP raised its stake in shares of MoonLake Immunotherapeutics by 156.2% in the second quarter. Allworth Financial LP now owns 1,714 shares of the company's stock worth $33,000 after purchasing an additional 1,045 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of MoonLake Immunotherapeutics in the second quarter valued at approximately $39,000. EverSource Wealth Advisors LLC boosted its position in shares of MoonLake Immunotherapeutics by 221.1% during the first quarter. EverSource Wealth Advisors LLC now owns 2,867 shares of the company's stock valued at $53,000 after buying an additional 1,974 shares during the last quarter. FNY Investment Advisers LLC purchased a new position in shares of MoonLake Immunotherapeutics during the second quarter valued at approximately $58,000. Finally, Quarry LP grew its holdings in MoonLake Immunotherapeutics by 8,400.0% during the third quarter. Quarry LP now owns 10,200 shares of the company's stock worth $119,000 after buying an additional 10,080 shares in the last quarter. 93.85% of the stock is owned by institutional investors.
MoonLake Immunotherapeutics Stock Down 4.1%
Shares of NASDAQ:MLTX opened at $11.25 on Wednesday. The business's 50 day simple moving average is $11.74 and its two-hundred day simple moving average is $16.20. The firm has a market cap of $957.49 million, a P/E ratio of -3.07 and a beta of 1.14. The company has a debt-to-equity ratio of 0.26, a quick ratio of 9.13 and a current ratio of 9.13. MoonLake Immunotherapeutics has a 52-week low of $9.46 and a 52-week high of $23.29.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.10). As a group, research analysts forecast that MoonLake Immunotherapeutics will post -3.57 EPS for the current fiscal year.
About MoonLake Immunotherapeutics
(
Get Free Report)
MoonLake Immunotherapeutics is a Switzerland-based clinical-stage biopharmaceutical company focused on developing treatments for inflammatory skin and joint diseases. The company was established in 2021 and is headquartered in Zug. Its lead investigational medicine, sonelokimab, is a nanobody designed to inhibit the inflammatory proteins IL-17A and IL-17F. MoonLake is studying the drug as a potential treatment for conditions including hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.